Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

NetScientific is a transatlantic healthcare IP commercialisation group.
We fund and develop companies that significantly improve the health and well-being of people with chronic diseases.

TESTIMONIALS

Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

OUR TEAM

Sector-specialist senior management team with extensive commercial experience.

  • Sir Richard Sykes, FRS

    Sir Richard Sykes, Non-Executive Chairman of the Group, joined NetScientific in 2008. Sir Richard spent thirty years working in the biotechnology and pharmaceutical industries, …

    Sir Richard Sykes, FRS
    Chairman

  • Francois Martelet, M.D.

    François Martelet, Chief Executive Officer, joined NetScientific Mid 2015. He brings over 20 years of biopharma experience and a proven track record of shaping and …

    Francois Martelet, M.D.
    Chief Executive Officer

  • Ian Postlethwaite

    Ian Postlethwaite, Chief Financial Officer, joined NetScientific in June 2016. He brings over 14 years of biopharma experience and a proven track record of …

    Ian Postlethwaite
    Chief Financial Officer & Company Secretary
See our Team

NEWS

Vortex Biosciences paves the way forward in CTC enumeration by introducing impedance measurements

Nov 8, 2018
-
News, RNS Announcements, Vortex BioSciences

London, UK – 08 November 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, has presented a …

Read More →
4 MIN READ

Vortex Biosciences and STRATEC GmbH announce global partnership to scale-up manufacturing for liquid biopsy platform

Nov 1, 2018
-
News, RNS Announcements, Vortex BioSciences

London, UK – 1 November 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, has entered into …

Read More →
5 MIN READ

Glycotest Inc. Completes $10 Million Series A Financing with Fosun Pharma

Oct 22, 2018
-
Glycotest, News, RNS Announcements

The following amendments have been made to the ‘Glycotest Completes $10m Series A Round with Fosun’ announcement (RNS Number: 6823E) released on 22 October 2018 at 07:00AM:   …

Read More →
7 MIN READ

EXECUTIVE INTERVIEW

 
NetScientific healthcare technology group